Small-cell lung cancer is recalcitrant cancer and the most aggressive form of lung malignancy. My research is focused on developing new therapies for small cell lung cancer in both preclinical and clinical settings. We are especially interested in identifying predictive biomarkers and drug resistance mechanisms. We use state-of-art genomic and high-throughput drug screenings to identify new targets and novel drug combinations. Our research employes cell lines, animal models, and patient samples.
Research keywords: translational research; preclinical; cancer biology
Basic information
| Pronouns: | He/Him/His |
| Mentoring statement: | Not provided. |
| Some former postdocs’ career outcomes: | Trainee 1 – Dr. Lisa Gesumaria becomes a Curation Scientist, Qiagen. Trainee 2 – Dr. Yanjin Liu becomes an Associate Specialist, University of California, San Francisco Trainee 3 – Dr. Anju Kumari becomes a postdoctoral scholar at National Cancer Institute, NIH |
Postdoc openings within the next year
| Number of postdoc positions: | 1 |
| Postdoc eligibility: | U.S. Citizens or Permanent Residents Current Visa-Holding Trainees in the U.S. International Trainees Outside the U.S. |